BioAtla (BCAB) Stock Price, News & Analysis

Company Overview

BioAtla, Inc. (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials. Lead programs include BA3011, a conditionally active antibody targeting cMet for solid tumors, and BA3071, a conditionally active T-cell–engaging bispecific targeting prostate‐specific membrane antigen (PSMA) in metastatic castration-resistant prostate cancer. The company’s research pipeline also features several discovery‐stage CAB molecules directed against tumor-associated antigens and immune checkpoints, reflecting its strategy to address high‐unmet‐need indications.

BioAtla serves a global patient population through internal research and development operations in the United States and China. The company’s R&D infrastructure integrates molecular engineering, translational biology and preclinical pharmacology, enabling rapid optimization of CAB candidates. In addition to its internal programs, BioAtla has entered into strategic collaborations and licensing agreements to accelerate development and broaden the therapeutic reach of its platform.

Led by President and Chief Executive Officer Christian S. Neal, BioAtla’s management team brings extensive experience in antibody engineering, clinical development and regulatory affairs. The company’s mission is to transform the safety and efficacy profile of biologic therapies by harnessing the precision of conditionally active molecules. As BioAtla advances its clinical portfolio, it aims to deliver innovative treatment options that improve patient outcomes and set new standards in targeted oncology therapy.

Key Stats

• Today's Range: $0.90 to $1.00
• 50-Day Range: $0.35 to $1.02
• 52-Week Range: $0.24 to $2.53
• Volume: 750,823 shs
• Average Volume: 979,746 shs
• Market Capitalization: $53.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Reduce

BioAtla Stock Analysis - MarketRank™

BioAtla scored higher than 12% of companies evaluated by MarketBeat, and ranked 912th out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for BioAtla.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BioAtla are expected to grow in the coming year, from ($1.46) to ($1.40) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BioAtla is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioAtla is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

BioAtla has a P/B Ratio of 3.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.34% of the outstanding shares of BioAtla have been sold short.

Short Interest Ratio / Days to Cover

BioAtla has a short interest ratio ("days to cover") of 5.5.

Change versus previous month

Short interest in BioAtla has recently increased by 8.29%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioAtla does not currently pay a dividend.

Dividend Growth

BioAtla does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.34% of the outstanding shares of BioAtla have been sold short.

Short Interest Ratio / Days to Cover

BioAtla has a short interest ratio ("days to cover") of 5.5.

Change versus previous month

Short interest in BioAtla has recently increased by 8.29%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

BioAtla has a news sentiment score of 1.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for BioAtla this week, compared to 1 article on an average week.

Search Interest

Only 2 people have searched for BCAB on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioAtla insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.22% of the stock of BioAtla is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

77.23% of the stock of BioAtla is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BCAB Stock Analysis - Frequently Asked Questions

How have BCAB shares performed this year?

BioAtla's stock was trading at $0.5912 at the start of the year. Since then, BCAB stock has increased by 53.9% and is now trading at $0.9101.

How were BioAtla's earnings last quarter?

BioAtla, Inc. (NASDAQ:BCAB) issued its earnings results on Thursday, August, 7th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by $0.02.
Read the conference call transcript.

When did BioAtla IPO?

BioAtla (BCAB) raised $150 million in an IPO on Wednesday, December 16th 2020. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies, Credit Suisse and BTIG acted as the underwriters for the IPO.

Who are BioAtla's major shareholders?

BioAtla's top institutional shareholders include Sheets Smith Investment Management (0.11%). Insiders that own company stock include Jay M Phd Short, Christian Vasquez, Lawrence Steinman and Sylvia Mcbrinn.
View institutional ownership trends.

How do I buy shares of BioAtla?

Shares of BCAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of BioAtla own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioAtla investors own include NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Netflix (NFLX) and Visa (V).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 10/13/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BCAB
• CIK: 1826892
• Web: www.bioatla.com
• Phone: 858-558-0708
• Fax: N/A
• Employees: 60
• Year Founded: 2007

Profitability

• EPS (Trailing Twelve Months): ($1.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$69.78 million
• Net Margins: N/A
• Pretax Margin: -541.04%
• Return on Equity: -1,177.18%
• Return on Assets: -137.51%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.24
• Quick Ratio: 1.24

Sales & Book Value

• Annual Sales: $11 million
• Price / Sales: 4.86
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.25 per share
• Price / Book: 3.64

Miscellaneous

• Outstanding Shares: 58,720,000
• Free Float: 52,133,000
• Market Cap: $53.44 million
• Optionable: Optionable
• Beta: 1.03